The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile
PHASE4Not yet recruitingINTERVENTIONAL
Enrollment
200
Participants
Timeline
Start Date
October 15, 2023
Primary Completion Date
October 15, 2026
Study Completion Date
November 15, 2026
Conditions
Stroke, Acute IschemicPCSK9 Inhibitor
Interventions
DRUG
Alirocumab
Initial alirocumab, single dose of 300mg, subcutaneous injection
Trial Locations (1)
138-736
Asan Medical Center, Seoul
All Listed Sponsors
lead
Sun U. Kwon
OTHER
NCT06083961 - The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile | Biotech Hunter | Biotech Hunter